Table 1. Clinical characteristics of the patients and controls in the NGS cohort, the validation cohort, and the prognostic cohort.
| Characteristic | NGS cohort | Validation cohort | Prognostic cohort | ||||||
|---|---|---|---|---|---|---|---|---|---|
| BPH controls | Localized PC | AdvPC | CRPC | BPH controls | Locally advanced or AdvPC | Hormone-suppressed PC | CRPC | Locally advanced or AdvPC | |
| No. | 8 | 16 | 9* | 12* | 58 | 62 | 14 | 15 | 94 |
| Age, years, mean (range) | 65.1 (54–70) | 68.1 (54–75) | 74.9 (69–82) | 73.7 (59–82) | 71.5 (54–90) | 71.4 (48–85) | 72.2 (52–78) | 69.6 (53–85) | 69.9 (52–86) |
| PSA at operation, ng/ml, mean±SD | 1.8±0.4 | 15.1±7.9 | 332.8±276.0 | 62.3±56.0 | 1.7±1.3 | 387.9±1239.3 | 9.8±15.7 | 193.6±387.3 | 277.8±959.5 |
| Operation, n (%) | |||||||||
| TUR-P | 8 | 0 | 1 | 12 | 58 | 44 (71.0) | 14 (100) | 15 (100) | 59 (62.8) |
| Radical prostatectomy | 0 | 16 | 8 | 0 | 18 (29.0) | 0 (0.0) | 0 (0.0) | 35 (37.2) | |
| Gleason score, n (%) | |||||||||
| 6 or less | 2 | 0 | 0 | 5 (8.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| 7 | 11 | 3 | 2 | 20 (32.3) | 2 (16.3) | 3 (20.0) | 42 (44.7) | ||
| 8 | 0 | 0 | 2 | 14 (22.6) | 3 (21.4) | 1 (6.7) | 17 (18.1) | ||
| 9 | 3 | 6 | 7 | 21 (33.9) | 8 (57.1) | 8 (53.3) | 32 (34.0) | ||
| 10 | 0 | 0 | 1 | 2 (3.2) | 1 (7.1) | 3 (20.0) | 3 (3.2) | ||
| TNM stage, n (%) | |||||||||
| T2 or T3, N0, M0 | 16 | 0 | 0 | 17 (27.4) | 1 (7.1) | 0 (0.0) | 47 (50.0) | ||
| T4 or metastatic | 0 | 9 | 12 | 45 (72.6) | 13 (92.9) | 15 (100) | 47 (50.0) | ||
*In the NGS cohort, four patients had biopsies of both their AdvPC and the CRPC that arose from it later.
Abbreviations: BPH, benign prostate hyperplasia; NGS, next-generation sequencing; PC, prostate cancer; AdvPC, advanced PC; PSA, prostate-specific antigen; SD, standard deviation; TUR-P, transurethral resection of the prostate.